<DOC>
	<DOCNO>NCT00389506</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine cyclophosphamide , work different way stop growth cancer cell , either kill cell stop divide . LMB-2 immunotoxin find cancer cell kill without harm normal cell . Giving fludarabine cyclophosphamide follow LMB-2 immunotoxin may kill cancer cell . PURPOSE : This clinical trial study well give fludarabine cyclophosphamide follow LMB-2 immunotoxin work treat patient Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Fludarabine Cyclophosphamide Followed By LMB-2 Immunotoxin Treating Patients With Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility pretreatment fludarabine phosphate cyclophosphamide prevent neutralization antibody patient CD25-positive Hodgkin 's lymphoma . Secondary - Determine response rate patient treat LMB-2 immunotoxin . - Determine response duration patient receive treatment . - Correlate serum level LMB-2 immunotoxin toxicity response patient . - Assess development neutralize antibody effect antibody blood level LMB-2 immunotoxin toxicity . - Correlate soluble Tac-peptide level treatment response patient . OUTLINE : This nonrandomized , pilot study . Patients receive fludarabine phosphate IV 30 minute cyclophosphamide IV 60 minute day 1-4 filgrastim ( G-CSF ) subcutaneously daily begin day 5 continue blood count recover . Beginning 4 week completion chemotherapy , patient receive LMB-2 immunotoxin IV 30 minute day 1 , 3 , 5 . Treatment repeat every 28 day 6 course absence disease progression . Blood obtain prior chemotherapy periodically LMB-2 immunotoxin therapy pharmacokinetic study measure lymphocyte subset . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically confirm CD25+ Hodgkin 's lymphoma At least 20 % malignant cell positive immunohistochemistry Stage IIIV disease Meets follow criterion : Failed standard chemotherapy Not eligible curative salvage radiotherapy chemotherapy Not eligible refuse bone marrow transplantation Measurable disease No patient whose serum neutralize LMB2 immunotoxin tissue culture , due either antitoxin antimouseIgG antibodies No patient whose serum neutralize &gt; 75 % activity 1 µg/mL LMB2 immunotoxin PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 50,000/mm³ Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ALT AST ≤ 2.5 time upper limit normal Albumin ≥ 3.0 g/dL Bilirubin ≤ 2.2 mg/dL ( &lt; 5 mg/dL Gilbert 's syndrome present ) Creatinine ≤ 1.4 mg/dL OR creatinine clearance ≥ 50 mL/min No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit study compliance No HIV hepatitis C positivity Hepatitis B surface antigen positivity allow provided patient receive lamivudine LVEF ≥ 45 % DLCO ≥ 50 % normal OR FEV_1 ≥ 60 % normal No active second malignancy require treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics No systemic cytotoxic chemotherapy within past 4 week No systemic steroid ( except stable dos prednisone ≤ 20 mg/day ) within past 4 week No monoclonal antibody therapy within past 12 week No prior LMB2 immunotoxin No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>